Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 9/20 | 0.39 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 5/20 | 0.39 |
| ▸ | AHR | P35869 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19995850 | 0.75 | ALDH1A1 (0.44) | BAZ2BTP53SMN1; SMN2 | |
| SCHEMBL26088619 | 0.74 | CNR2 (0.47) | CNR2CNR1AHRHSD17B10 | |
| SCHEMBL2736907 | 0.73 | CNR2 (0.49) | CNR2CNR1AHRHSD17B10 | |
| SCHEMBL26089078 | 0.73 | CNR2 (0.49) | CNR2CNR1AHRHSD17B10 | |
| SCHEMBL13990928 | 0.72 | CNR2 (0.47) | CNR2CNR1AHRHSD17B10 | |
| SCHEMBL19995853 | 0.71 | ALDH1A1 (0.44) | BAZ2BSMN1; SMN2 | |
| SCHEMBL2736618 | 0.71 | CNR2 (0.41) | CNR2CNR1 | |
| SCHEMBL26088272 | 0.71 | CNR2 (0.44) | CNR2CNR1AHRHSD17B10 | |
| SCHEMBL2736562 | 0.71 | CNR2 (0.52) | CNR2CNR1AHR | |
| SCHEMBL30617776 | 0.70 | CNR2 (0.46) | CNR2CNR1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-7652141-B2 | Immunosuppressants, analgesics, antiinflammatory agents | SHIONOGI & CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-20070027144-A1 | Novel use of cannabinoid receptor agonist | SHIONOGI & CO., LTD. (JP) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027144-A1 | Novel use of cannabinoid receptor agonist | CNR2, CNR1, OPRM1 | BRPF1 1871/4885CNR2 1/4885BAZ2B 524/4885 |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | CNR2, CNR1, NPY2R | BRPF1 1023/4885CNR2 1/4885BAZ2B 958/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | BRPF1 1589/4885CNR2 2/4885BAZ2B 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.